Call 1-888-805-4555 for 24/7 on-call assistance

Yellow clipboard icon

Patient Access & Insurance Coverage

Coverage and reimbursement for Bristol Myers Squibb CAR T cell therapies may vary based on payer-specific requirements, potential site/setting of care, and patient-specific benefits.

Benefit verification (BV) with a patient’s payer is critical to help identify specific considerations for each appropriate candidate for Bristol Myers Squibb CAR T cell therapies. Our Insurance Coverage Lookup tool can provide information to assist in the BV process, or Cell Therapy 360® can provide BV assistance to verify patient-specific coverage requirements.

Download the CAR T BV checklist for a helpful guide on the type of information that needs to be confirmed during the BV process for CAR T cell therapies.

Information icon
KEY FACT

Treatment centers should confirm access prior to apheresis scheduling, including BV, prior authorization (PA) approval, and single case agreement (if required).

For questions, please contact your Bristol Myers Squibb Account Representative or call Cell Therapy 360 at 1-888-805-4555.

Bristol Myers Squibb is committed to delivering optimal patient and customer experience with cellular therapies. This information will help appropriate patients get access to our CAR T cell therapies and help treatment centers navigate the reimbursement process.

This information is provided for educational purposes only. Bristol Myers Squibb cannot guarantee insurance coverage or reimbursement. Coverage and reimbursement may vary significantly by payer, plan, patient, and setting of care and is subject to frequent change. It is the sole responsibility of the healthcare provider to select the proper codes and ensure the accuracy of all statements used in seeking coverage and reimbursement for an individual patient.

For more information on coverage for CAR T cell therapies, please click each payer type below.

CAR T CELL THERAPY RESOURCES

PRODUCT-SPECIFIC INFORMATION AND CODES

CAR=chimeric antigen receptor; R/R=relapsed or refractory.

This information is provided for educational purposes only. Bristol Myers Squibb cannot guarantee insurance coverage or reimbursement. Coverage and reimbursement may vary significantly by payer, plan, patient, and setting of care and is subject to frequent change. It is the sole responsibility of the healthcare provider to select the proper codes and ensure the accuracy of all statements used in seeking coverage and reimbursement for an individual patient.

References

  1. Centers for Medicare & Medicaid Services. Decision memo for chimeric antigen receptor (CAR) T-cell therapy for cancers. Accessed April 16, 2025. https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=N&NCAId=291
  2. Medicare.gov. Medicare costs. Accessed April 16, 2025. https://www.medicare.gov/basics/costs/medicare-costs
  3. Centers for Medicare & Medicaid Services Medical Learning Network. Billing instructions for beneficiaries enrolled in Medicare Advantage (MA) plans for services covered by decision memo CAG-00451N. Article Release Date October 24, 2019. Accessed April 16, 2025. https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/Downloads/SE19024.pdf
  4. Centers for Medicare & Medicaid Services. Medicare managed care manual. Chapter 4 - benefits and beneficiary protections. Revised April 22, 2016. Accessed April 16, 2025. https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/downloads/mc86c04.pdf
  5. Freed M, Biniek JF, Damico A, Neuman T. Medicare Advantage in 2024: premiums, out-of-pocket limits, cost sharing, supplemental benefits, prior authorization, and star ratings. KFF. Published August 8, 2024. Accessed April 16, 2025. https://www.kff.org/medicare/issue-brief/medicare-advantage-in-2024-premiums-out-of-pocket-limits-supplemental-benefits-and-prior-authorization/#
  6. Centers for Medicare & Medicaid Services. Medicare Drug & Health Plan Contract Administration Group. Published May 6, 2024. Accessed April 16, 2025. https://mabenefitsmailbox.lmi.org/MABenefitsMailbox/S3Browser/GetFile?path=Final%20CY%202025%20Standards%20for%20Part%20C%20Benefits.pdf
  7. 2024 employer health benefits survey. KFF. Published October 9, 2024. Accessed April 16, 2025. https://www.kff.org/health-costs/report/2024-employer-health-benefits-survey/


Legal Notice           Privacy Policy          Your Privacy Choices          Site Map

This site is intended for U.S. audiences only. 

© 2025 Bristol-Myers Squibb Company. All rights reserved.
CELL THERAPY 360 and the related logo are trademarks of Celgene Corporation, a Bristol Myers Squibb company. All other trademarks are the property of their respective owners.

HE-US-2500159 06/25